Allergy Therapeutics (AGY) - Cash Flow Conversion Efficiency

Latest as of June 2025: 0.748x

Based on the latest financial reports, Allergy Therapeutics (AGY) has a cash flow conversion efficiency ratio of 0.748x as of June 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (GBX-21.09 Million ≈ $-2.57K USD) by net assets (GBX-28.19 Million ≈ $-3.43K USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See Allergy Therapeutics (AGY) liquidity interval to measure how many days the company can operate on defensive assets alone.

Allergy Therapeutics - Cash Flow Conversion Efficiency Trend (2002–2025)

This chart illustrates how Allergy Therapeutics's cash flow conversion efficiency has evolved over time, based on yearly financial data.

Allergy Therapeutics Competitors by Cash Flow Conversion Efficiency

The table below lists competitors of Allergy Therapeutics ranked by their cash flow conversion efficiency.

Company	Cash Flow Conversion Efficiency
X2M Connect Ltd AU:X2M	-0.024x
Combigene AB ST:COMBI	-0.087x
CF Energy Corp V:CFY	0.026x
VIA OPTRONICS AG SP.ADS/1 F:5UU1	N/A
Tatton Asset Management plc LSE:TAM	0.130x
ROKMASTER Resources Corp V:RKR	0.203x
Strike Resources Ltd AU:SRK	-0.102x
Custodian REIT PLC LSE:CREI	0.025x

Annual Cash Flow Conversion Efficiency for Allergy Therapeutics (2002–2025)

The table below shows the annual cash flow conversion efficiency of Allergy Therapeutics from 2002 to 2025. For the full company profile with market capitalisation and key ratios, see market cap of Allergy Therapeutics.

Year	Net Assets	Operating Cash Flow	Cash Flow Conversion Efficiency	Change
2025-06-30	GBX-28.19 Million ≈ $-3.43K	GBX-28.72 Million ≈ $-3.49K	1.019x	+111.76%
2024-06-30	GBX3.71 Million ≈ $451.28	GBX-32.14 Million ≈ $-3.91K	-8.665x	+42.10%
2023-06-30	GBX2.07 Million ≈ $251.37	GBX-30.92 Million ≈ $-3.76K	-14.964x	-3904.84%
2022-06-30	GBX37.77 Million ≈ $4.59K	GBX-14.11 Million ≈ $-1.72K	-0.374x	-312.95%
2021-06-30	GBX48.53 Million ≈ $5.91K	GBX8.52 Million ≈ $1.04K	0.175x	-37.42%
2020-06-30	GBX43.78 Million ≈ $5.33K	GBX12.28 Million ≈ $1.49K	0.280x	+88.05%
2019-06-30	GBX37.56 Million ≈ $4.57K	GBX5.60 Million ≈ $681.36	0.149x	+190.33%
2018-06-30	GBX23.03 Million ≈ $2.80K	GBX-3.80 Million ≈ $-462.59	-0.165x	-2878.67%
2017-06-30	GBX29.96 Million ≈ $3.65K	GBX178.00K ≈ $21.66	0.006x	+101.52%
2016-06-30	GBX30.32 Million ≈ $3.69K	GBX-11.84 Million ≈ $-1.44K	-0.390x	-530.91%
2015-06-30	GBX34.47 Million ≈ $4.19K	GBX3.12 Million ≈ $379.98	0.091x	-37.14%
2014-06-30	GBX15.07 Million ≈ $1.83K	GBX2.17 Million ≈ $264.39	0.144x	-13.04%
2013-06-30	GBX14.67 Million ≈ $1.79K	GBX2.43 Million ≈ $295.90	0.166x	-16.01%
2012-06-30	GBX14.59 Million ≈ $1.78K	GBX2.88 Million ≈ $350.41	0.197x	+120.83%
2011-06-30	GBX2.14 Million ≈ $260.25	GBX-2.03 Million ≈ $-246.63	-0.948x	-316.36%
2010-06-30	GBX3.89 Million ≈ $472.81	GBX1.70 Million ≈ $207.08	0.438x	+2206.97%
2009-06-30	GBX-23.18 Million ≈ $-2.82K	GBX-440.00K ≈ $-53.54	0.019x	-98.89%
2008-06-30	GBX-11.29 Million ≈ $-1.37K	GBX-19.32 Million ≈ $-2.35K	1.711x	+177.93%
2007-06-30	GBX8.60 Million ≈ $1.05K	GBX-18.88 Million ≈ $-2.30K	-2.196x	-786.27%
2006-06-30	GBX32.70 Million ≈ $3.98K	GBX-8.10 Million ≈ $-985.90	-0.248x	-8630.66%
2005-06-30	GBX20.08 Million ≈ $2.44K	GBX-57.00K ≈ $-6.94	-0.003x	-101.05%
2004-06-30	GBX7.08 Million ≈ $860.94	GBX1.91 Million ≈ $231.91	0.269x	-28.68%
2003-06-30	GBX5.55 Million ≈ $674.91	GBX2.10 Million ≈ $254.90	0.378x	-17.28%
2002-06-30	GBX-4.40 Million ≈ $-535.11	GBX-2.01 Million ≈ $-244.32	0.457x	--

About Allergy Therapeutics

LSE:AGY UK Drug Manufacturers - Specialty & Generic

Market Cap

$5.23 Million

GBX42.99 Billion GBX

Market Cap Rank

#28458 Global

#464 in UK

Share Price

GBX7.00

Change (1 day)

-6.42%

52-Week Range

GBX7.00 - GBX12.10

All Time High

GBX38.50